Corvus Pharmaceuticals Inc.

2.25-0.1000-4.26%Vol 210.41K1Y Perf -48.63%
Jul 23rd, 2021 16:00 DELAYED
BID2.23 ASK2.24
Open2.40 Previous Close2.35
Pre-Market- After-Market2.25
 - -  - -%
Target Price
6.50 
Analyst Rating
Strong Buy 1.00
Potential %
188.89 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap86.20M 
Earnings Rating
Sell
Price Range Ratio 52W %
4.90 
Earnings Date
29th Jul 2021

Today's Price Range

2.232.40

52W Range

2.075.74

5 Year PE Ratio Range

-6.30-3.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.60%
1 Month
-19.93%
3 Months
-19.93%
6 Months
-44.44%
1 Year
-48.63%
3 Years
-78.47%
5 Years
-84.14%
10 Years
-

TickerPriceChg.Chg.%
CRVS2.25-0.1000-4.26
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.33-0.34-3.03
Q04 2020-0.32-0.35-9.38
Q03 2020-0.25-0.33-32.00
Q02 2020-0.30-0.36-20.00
Q01 2020-0.40-0.44-10.00
Q04 2019-0.33-0.38-15.15
Q03 2019-0.40-0.377.50
Q02 2019-0.42-0.44-4.76
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.350.00-
9/2021 QR-0.406.98Positive
12/2021 FY-1.3915.24Positive
12/2022 FY-0.9846.15Positive
Next Report Date29th Jul 2021
Estimated EPS Next Report-0.32
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume210.41K
Shares Outstanding38.31M
Trades Count855
Dollar Volume5.73M
Avg. Volume575.46K
Avg. Weekly Volume229.79K
Avg. Monthly Volume218.91K
Avg. Quarterly Volume306.10K

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) stock closed at 2.25 per share at the end of the most recent trading day (a -4.26% change compared to the prior day closing price) with a volume of 210.51K shares and market capitalization of 86.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Corvus Pharmaceuticals Inc. CEO is Richard A. Miller.

The one-year performance of Corvus Pharmaceuticals Inc. stock is -48.63%, while year-to-date (YTD) performance is -36.8%. CRVS stock has a five-year performance of -84.14%. Its 52-week range is between 2.07 and 5.74, which gives CRVS stock a 52-week price range ratio of 4.90%

Corvus Pharmaceuticals Inc. currently has a PE ratio of -23.10, a price-to-book (PB) ratio of 0.94, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -4.94%, a ROC of -6.08% and a ROE of -5.86%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Corvus Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. Corvus Pharmaceuticals Inc.’s next earnings report date is 29th Jul 2021.

The consensus rating of Wall Street analysts for Corvus Pharmaceuticals Inc. is Strong Buy (1), with a target price of $6.5, which is +188.89% compared to the current price. The earnings rating for Corvus Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Corvus Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Corvus Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.78, ATR14 : 0.14, CCI20 : -86.44, Chaikin Money Flow : -0.02, MACD : -0.12, Money Flow Index : 15.96, ROC : -12.11, RSI : 34.58, STOCH (14,3) : 28.13, STOCH RSI : 0.67, UO : 49.67, Williams %R : -71.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Corvus Pharmaceuticals Inc. in the last 12-months were: Peter A. Thompson (Buy at a value of $4 499 999), Richard A. Miller (Buy at a value of $449 999)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing small-molecule and antibody agents that target the immune system to treat patients with cancer. The firm's pipeline includes CPI-006, CPI-818, CPI-935, and others.

CEO: Richard A. Miller

Telephone: +1 650 900-4520

Address: 863 Mitten Road, Burlingame 94010, CA, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

41%59%

Bearish Bullish

61%39%

News

Stocktwits